Asclepii develops advanced wound care solutions centered on regenerative medicine principles. Their flagship product, Poseidon™, is an FDA-cleared nanosilver hydrogel dressing that promotes moisture balance and topical wound management. This dressing demonstrates superior clinical outcomes, achieving high rates of infection-free healing faster than leading market alternatives.
Funding
Funding not disclosed
Founders
Product
Problem
Current regenerative medicine lacks scalable solutions between cell therapies and traditional wound care, hindering effective treatment of chronic wounds and limiting progress in organ manufacturing. Existing technologies fail to adequately promote cell-to-cell and cell-to-matrix interactions necessary for optimal tissue regeneration.
Solution
Asclepii develops Artemis™, a highly scalable tissue regeneration matrix designed to bridge the gap between cell therapy and conventional bandages. Artemis™ enhances cell adhesion, proliferation, and differentiation, leading to improved wound healing outcomes and reduced scarring. The matrix's adaptable nature makes it suitable for a wide range of regenerative medicine applications, from chronic wound care to potential organ manufacturing. By maximizing cell interactions and providing a supportive environment, Artemis™ empowers next-generation therapeutics and accelerates tissue regeneration processes.
Target Audience
The primary target audience includes researchers and clinicians in regenerative medicine, wound care specialists, and biotechnology companies focused on developing advanced therapies.
Features
- Scalable scaffold for regenerative medicine applications
- Enhanced cell-to-cell and cell-to-matrix interactions
- Adaptable matrix suitable for various tissue types
- Promotes cell adhesion, proliferation, and differentiation
- Reduces scarring in wound healing